subslover
1 month ago
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.
NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.
This pioneering study, conducted by a distinguished team of researchers including Carla Yuede, Kate M. Reardon, Ryan T. Harrigan, and John R. Cirrito, among others, highlights HT-ALZ's profound impact on Alzheimer's pathology. By specifically antagonizing the NK1 receptor, HT-ALZ not only reduces soluble Aß levels in the brain's interstitial fluid but also significantly diminishes anxiety-like behavior and enhances cognitive function in preclinical models.
The research presents compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment. While the effects on plaque deposition and Aß levels were inconclusive, the treatment's cognitive benefits suggest that HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.
HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease, offering a beacon of hope.
Hoth Therapeutics remains committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial activation and brain inflammation. The company is optimistic about HT-ALZ's path toward. The full manuscript of the study will be published later this year and we look forward to a presentation of the results by the scientists named above who will be sharing this data at an Alzheimer's Research Center group at Washington University in St Louis.
For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com
About Hoth Therapeutics, Inc.
Golden Cross
4 months ago
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
December 27 2023 - 08:21AM
PR Newswire (US)
Alert
Print
Share On Facebook
NEW YORK, Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.
(PRNewsfoto/Hoth Therapeutics Inc.)
This First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose-ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. More information can be found at clinicaltrials.gov.
"We are very pleased to have received approval for our FIH clinical trial," said Hoth Therapeutics Chief Executive Officer, Robb Knie. "We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001. Coupled with approval at Washington University of St. Louis and MD Anderson Cancer Center, University of Miami will be our third site approved to host our trial and bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments. I look forward to updating our investors and patients on this ongoing trial in the first quarter of 2024."
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-expansion-of-fda-cleared-first-in-human-clinical-trial-for-cancer-patients-of-ht-001-at-university-of-miami-302022630.html
SOURCE Hoth Therapeutics, Inc.
subslover
11 months ago
Tell me how this can be.The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at May 9, 2023 was 3,302,113.
The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at May 9, 2023 was 3,302,113.
subslover
12 months ago
Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge
Anthony Zook, formerly of Astra Zeneca, to be named Chairman of The Board
Mike Tilton to be named Chief Executive Officer of the Combined Company
Algorithm pipeline focused on Pulmonary Arterial Hypertension (PAH) a rare disease with a
prevalence of ~100,000 patients in the US
NEW YORK, April 26, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced it has signed a Letter of Intent to merge with Algorithm Sciences, Inc. ("Algorithm") a company focused on Pulmonary Arterial Hypertension (PAH). The combined company will be named Algorithm Sciences, Inc. and be led by experienced biopharma executives, including Mike Tilton as CEO, David Cavalier as CFO and Anthony Zook, Algorithm's current chairman of the board, who will be nominated as chairman of the combined company's board of directors. Algorithm will become the majority holders of Hoth's outstanding stock by way of a merger.
"Today's announcement is an exciting chapter for Hoth and its shareholders," stated Robb Knie, CEO of Hoth. "The combination of assets in the combined company translates to additional billions of dollars in market opportunity for current shareholders. Algorithm's executive team along with its science professionals brings a seasoned executive focus on commercialization and monetization of the now robust advanced pipeline."
Mike Tilton, CEO of Algorithm commented, "Today's announced business combination achieves a new milestone for us and spotlights the tremendous opportunity of our lead therapeutic for those suffering from PAH. We are thrilled with the progress of our development program and look forward to achieving our near-term goal of filing an Investigational New Drug (IND) Application with the FDA."
The global pulmonary arterial hypertension treatment market size was valued at $7.2 billion in 2021, and is projected to reach $12 billion by 2031, growing at a CAGR of 5.2% from 2021 to 2031. (https://www.alliedmarketresearch.com/pah-treatment-market) Algorithm is uniquely positioned to take advantage of this opportunity.
On a pro forma basis and based upon the number of shares of Hoth common stock to be issued in the merger, current Hoth shareholders are currently anticipated to own approximately 14% of the combined company and current Algorithm shareholders are currently anticipated to own approximately 86% of the combined company. The Boards of Directors of both Hoth and Algorithm have unanimously approved the letter of intent. The completion of the transaction remains subject to a number of conditions, including, but not limited to, among others, the completion of due diligence to Hoth's satisfaction, the negotiation and execution of definitive documentation and satisfaction of the conditions contained therein, completion of any required stock exchange and regulatory reviews, and approval of the transaction by Hoth's stockholders and Algorithm's stockholders. Accordingly, no assurances can be made by either party that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Terms and conditions of the merger will be forthcoming as the two companies reach a definitive merger agreement.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of any business combination or stockholder meeting. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Additional Information about the Proposed Transactions and Where to Find It
In connection with the proposed transaction, and following execution of a definitive transaction agreement, Hoth will file a proxy statement with the Securities and Exchange Commission (SEC). The materials to be filed by Hoth with the SEC may be obtained free of charge at the SEC's web site at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF HOTH ARE URGED TO READ THE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTIONS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products an
Register to chat with like-minded investors on our interactive forums.
TrendTrade2016
4 weeks ago
Awl416
4 weeks ago
Monksdream
1 month ago
hawkshaw812
7 months ago
81vette
7 months ago
AJ Freely
9 months ago
maverick_1
11 months ago
m0n
11 months ago
TheFinalCD
11 months ago
surf1944
11 months ago
glenn1919
1 year ago
buccaneer1961
1 year ago
Hot Features
Premium
